RESUMO
To reduce the burden caused by an increased elderly population and to provide efficient service resources, scholars worldwide have proposed and applied smart elderly care. This paper summarizes the hotspots of the existing literature and explores the research frontiers to ignite future research. CiteSpace software was used to conduct a scientometric analysis of high-quality literature collected from both the China National Knowledge Infrastructure (CNKI) and the Web of Science (WOS). Based on the results of the basic situation description, this article highlights six research hotspots in CNKI and 11 research themes in WOS. In addition, it offers three major evolution stages and three future research directions for smart elderly care research. This paper provides a holistic overview of the smart elderly care literature from two major global databases. The results will contribute to healthcare policy designers, practitioners, and developers by giving them comprehensive knowledge and generating strategies to enhance elderly people's quality of life.
Assuntos
Conhecimento , Qualidade de Vida , Humanos , Idoso , China , Bases de Dados Factuais , PrevisõesRESUMO
Internationalization of Traditional/Complementary Medicine (T&CM) products is important for initiating and sustaining developments in this field. Particularly for traditional Chinese medicines (TCMs), the global market continues to expand due to an interest in the potential clinical benefits of traditional approaches that are largely considered lower risk and lower cost than many conventional treatments. While the benefits of internationalization hold clear advantages for the business of T&CM products, keeping abreast of regulatory processes in different countries and regions that regularly revise market entry requirements is challenging. At present, the regulations of T&CM products are country specific and largely based on a risk-based assessment with a focus on protecting the consumer. To date, systematic analysis of these regulatory differences between countries and regions is limited. Publically available information about the legal requirements for the market entry of T&CM products were obtained from the relevant regulatory authority's websites for selected countries and regions (Macau-China, Hong Kong-China, Singapore, Australia, Canada, the European countries and the US). The market entry requirements in terms of quality, safety and efficacy of T&CM products for each country were analyzed and compared. Major differences were identified in the classification of T&CM products, market entry pathways, requirements of compliance with Good Manufacturing Practices; and level of evidence to demonstrate safety and efficacy based on historical use, non-clinical and clinical studies. Variations in the evaluation standards adopted by regulatory authorities pose a number of barriers and opportunities for the internationalization of T&CM products and have great implications for internationalization of TCMs from the sponsors' and the regulators' perspectives.